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Current treatments for African trypanosomiasis are either toxic, costly, difficult to administer, 
or prone to elicit resistance. This study evaluated the activity of bisnaphthalimidopropyl 
(BNIP) derivatives against Trypanosoma brucei. BNIPDiaminobutane (BNIPDabut), the most 
active of these compounds, showed in vitro inhibition in the single-unit nanomolar range, 
similar to the activity in the reference drug pentamidine, and presented low toxicity and 
adequate metabolic stability. Additionally, using a murine model of acute infection and live 
imaging, a significant decrease in parasite load in BNIPDabut-treated mice was observed. 
However, cure was not achieved. BNIPDabut constitutes a new scaffold for 
antitrypanosomal drugs that deserves further consideration. 
TEXT 
African trypanosomiasis is an infectious disease caused by parasites of the species 
Trypanosoma brucei. The parasite is transmitted by an insect vector, the tsetse fly (Glossina 
spp.). The disease is distributed mainly on the African continent, with distinct subspecies 
causing different forms of human disease. T. brucei gambiense produces a chronic form of 
infection that may last for years and was responsible for nearly 98% of trypanosomiasis cases 
in the past decade. The acute form is caused by T. brucei rhodesiense and usually kills the 
host within weeks, accounting for the remaining 2% of reported cases (1, 2). 
Since vaccination remains elusive and vector control strategies are frequently insufficient, 
chemotherapy is still the most efficient option for controlling the disease (2–5). However, the 
drugs in current use have many drawbacks, mostly related to cost, effectiveness, toxicity, 
difficulty of administration, and appearance of resistance (6). Therefore, the development of 
new drugs is urgently needed. 
Bisnaphthalimidopropyl (BNIP) derivatives have been shown to possess anticancer activity 
(7–11) and to have activity against a related trypanosomatid, Leishmania infantum (12–14). 
The potential activity of three BNIP derivatives previously synthetized (>96% pure [10, 11, 
15]), namely, BNIPDiaminobutane (BNIPDabut), BNIPDiaminoheptane (BNIPDahep), and 
BNIPDiaminooctane (BNIPDaoct) (Fig. 1A), against T. brucei brucei Lister 427 bloodstream 
forms (BSFs), was investigated. These derivatives were selected from a series of compounds 
on the basis of preliminary studies of bioavailability and in vitro and in vivo activity against T. 
brucei and L. infantum (12; our unpublished data). The in vitro antiparasitic activity was 
assessed using a resazurin assay, as previously described, with minor modifications 
(incubation with 10
3
 parasites/well, in 200 μl [16]). All three BNIPs demonstrated a potent 
inhibitory effect on parasite growth, with a 50% inhibitory concentration (IC50) within the 
nanomolar range (Fig. 1B; Table 1). BNIPDabut was the most active compound, with a mean 
IC50 (± standard deviation [SD]) of 2.4 ± 1.0 nM, similar to that of the reference drug 
pentamidine (mean IC50 [± SD], 2.9 ± 0.7 nM; Table 1). Since this class of compounds has 
been described as a group of inhibitors of the L. infantum Silent information regulator 2-related 
protein 1 (LiSir2rp1; GenBank accession number AAN39039.1) (15), we evaluated whether 
inhibition of the T. brucei orthologue TbSir2rp1 (GenBank accession number AAX70528.1) is 
a possible mechanism of action. Whereas BNIPDabut was shown to inhibit the NAD
+
-
dependent deacetylase activity of TbSir2rp1 with an IC50 (± SD) of 155 ± 42 μM, suggesting 
that this is not the major mechanism of action (data not shown), LiSir2rp1 was inhibited with 
an IC50 (± SD) of 35.0 ± 5.8 μM (15). The 47% identity between LiSir2rp1 and TbSir2rp1 
obtained by protein sequence alignment (Clone Manager 9, BLOSUM 62 scoring matrix) 
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might explain the differences observed (17). Moreover, no correlation between the enzymatic 
inhibition and activity toward T. brucei parasites was observed. To evaluate in vitro toxicity 
toward mammalian cells, all the compounds were studied with the 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide assay (18) in THP-1–derived macrophages and two 
primary cell cultures, rat cortical neurons and mouse hepatocytes (Table 2). The 50% 
cytotoxic concentration (CC50) values for these molecules translate into selectivity indexes 
(SIs) higher than 100 (SI = CC50/IC50). All the BNIP derivatives exhibited a high SI, with 
BNIPDabut in particular being at least 800 times more selective toward T. brucei parasites. All 
the BNIPs had potency and selectivity that warranted additional characterization (Table 2). To 
further evaluate the potential toxic effects of BNIPs in host cells, a set of in vitro assays was 
performed in hepatocytes and neuronal primary cells. These assays evaluated different 
possible mechanisms of toxicity based on (i) reactive oxygen species determination 
(chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate [CM-H2DCFDA] probe, by high 
content analysis [HCA]), (ii) mitochondrial dysfunction (tetramethylrhodamine, methyl ester 
[TMRM] probe, by HCA), (iii) membrane integrity (lactate dehydrogenase quantification), (iv) 
apoptosis (caspase 3/7 activation), (v) either DNA damage for hepatocytes (H2AX antibody, 
by HCA) or neurite outgrowth for neurons (anti-tubulin III antibody, by HCA), (vi) cell viability 
as measured by WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium sodium salt probe], and (vii) Hoechst staining for nuclear detection. Nimesulide 
(400 μM) was included as a positive control and the vehicle as a neutral control (19–21). The 
relative percent deviation from the neutral control was quantified and assigned with a number 
from 0 to 5 (0 [0% to 20% deviation], 1 [20% to 40%], 2 [40% to 60%], 3 [60% to 100%], 4 
[100% to 1,000%], 5 [>1,000% deviation]). The sum of these values was ranked posteriorly to 
create combined injury criteria that varied from no injury (0) to low injury (1 to <5), moderate 
injury (≥5 to <12), and high injury (≥12). All BNIPs showed a dose-dependent injury score 
close to that of pentamidine in both cell types (Fig. 2A and B). BNIPDabut had a toxicity profile 
indistinguishable from that of the reference drug pentamidine. 
To infer metabolic stability, mouse microsomes were incubated over 45 min with each 
compound at 5 μM, and each drug was quantified by liquid chromatography-tandem mass 
spectrometry. Similarly to pentamidine, BNIPDabut was more stable than BNIPDahep and 
BNIPDaoct; 95% to 100% of the drug was not metabolized (Table 3). This high metabolic 
stability is an indicator that the molecule is not easily subjected to common inactivation or loss 
of potency by reactions catalyzed by liver enzymes and is kept intact in circulation for longer 
periods. 
To determine the pharmacokinetics of BNIPDabut, a 10-mg/kg dose was administered to 
BALB/c mice by intravenous injection. Five minutes later, a concentration of 58 nM was 
achieved and, during the following 24 h, remained higher than 41 nM (data not shown); thus, 
the concentration was approximately eight times higher than the calculated IC90. 
Taking into consideration the previous results, we chose BNIPDabut for in vivo efficacy 
studies. All the experiments involving animals were carried out in accordance with the Institute 
for Molecular and Cell Biology Animal Ethics Committees and the Portuguese and European 
Authorities for Animal Health guidelines. T. brucei brucei Lister 427 parasites were transfected 
with a construct kindly provided by M. Taylor, in which the red-shifted luciferase gene 
(PpyRE9h) is flanked by 5′VSG/3′tubulin (22). After transfection, clones were screened for 
bioluminescent signal, and the ones that expressed the highest levels were selected. Their in 
vitro growth was compared with that of wild-type parasites and was found to be similar (data 
not shown). In vitro detection limits were also analyzed for BSFs in a 96-well plate and 
determined to be approximately 2,500 cells (data not shown). Female BALB/c mice were 
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inoculated intraperitoneally with 10
4
 BSFs. Three days after infection, five groups of mice (n = 
4 per group) were treated intravenously with (i) saline, (ii) pentamidine at 2.5 mg/kg/day, (iii) 
dimethyl sulfoxide (DMSO) at 16.7%, or (iv) BNIPDabut at a dose of 10 or 20 mg/kg/day. 
Pentamidine was administered for 4 days, while BNIPDabut and the respective vehicle 
(DMSO at 16.7%) were administered for 6 days (Fig. 3A). No adverse effects were observable 
following any administration regimen. Treatment efficacy was followed through whole-animal 
live imaging using an IVIS Lumina LT (PerkinElmer). Parasitemia was also assessed, and 
animals were euthanized after reaching a parasite concentration of 10
8
 parasites/ml. Similarly 
to pentamidine, two administrations of either 10 or 20 mg/kg BNIPDabut efficiently reduced 
parasitemia below the detection limit (5 × 10
4
/ml) (Fig. 3B). However, whole-mouse imaging 
revealed that a reduction of bioluminescent signal to the background level (obtained with 
noninfected mice) was achieved only in mice treated with 20 mg/kg of BNIPDabut during at 
least 5 consecutive days, as opposed to 2 days of treatment for the pentamidine group. 
Although treatment with 20 mg/kg BNIPDabut apparently cleared the infection, cure was not 
achieved; the parasite burden relapsed when treatment was stopped (Fig. 3B). Indeed, 
BNIPDabut (10 and 20 mg/kg) treatment increased survival of the mice, but in contrast to 
those that received pentamidine, these animals were not cured (Fig. 3C). A hypothesis is that 
BNIPDabut, although highly trypanocidal, cannot reach and clear all parasites due to potency, 
distribution, or both. A frequent observation was that the recurrence of parasitemia was 
preceded by imaging of parasite loads in the peritoneal zone, where animals were originally 
injected with the parasites. It has been demonstrated that trypanosomes invade extravascular 
tissues as a defense mechanism against host immunity and that this process may be related 
to relapses after treatment interruption (23, 24). Indeed, the presence of parasites in the 
extravascular tissues might explain the discrepancy of radiance values between days 4 and 
12, while average parasitemia levels remained similar in mice treated with BNIPDabut (10 or 
20 mg/kg) (Fig. 3C). Nonetheless, it remains to be elucidated whether BNIPDabut is active in 
a mouse model of late-stage disease, as this is the central objective in drug discovery against 
human African trypanosomiasis. Additional chemical modifications to BNIPDabut may improve 
potency and/or distribution of the drug while maintaining or improving the toxicity and 
metabolism profiles. 
In conclusion, this work demonstrates that BNIPDabut has potent in vitro and in vivo 
antitrypanosomal activity with acceptable toxicity and high metabolic stability. However, 
chemical modifications are needed to improve its pharmacodynamic and/or pharmacokinetic 
properties. 
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Table 1. In vitro activity of BNIP derivatives against Trypanosoma brucei brucei L427 bloodstream forms. 
 
 
Table 2. In vitro cytotoxicity of BNIP derivatives in different cell types. 
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Table 3. Mouse microsomal stability. 
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Figure 1. In vitro antitrypanosomal activity of BNIP compounds. (A) Chemical structures of pentamidine and the 
BNIP derivatives BNIPDabut, BNIPDahep, and BNIPDaoct. (B) Growth inhibition curves of Trypanosoma brucei 
brucei BSFs incubated in vitro with the indicated concentrations of pentamidine, BNIPDabut, BNIPDahep, or 
BNIPDaoct for 72 h. Parasite density was evaluated using resazurin. Dots and error bars represent the means 




Figure 2. In vitro toxicity of BNIP derivatives. (A) Hepatotoxicity injury score. The score was calculated as the sum of 
individual scores obtained from a panel of in vitro cytotoxicity assays that include (i) measurement of reactive oxygen 
species (ROS) using CM-H2DCFDA and cell imaging by HCA, (ii) assessment of mitochondrial dysfunction 
measured by TMRM probe dynamics in cells and imaged by HCA, (iii) membrane integrity assayed by lactate 
dehydrogenase quantification, (iv) DNA damage by imaging with H2AX antibody and HCA, (v) apoptosis by caspase 
3/7 activation, (vi) Hoechst staining for nuclear detection, and (vii) cell viability by WST-8 probe. Nimesulide (400 M), 
an approved drug with a mild toxicological profile, was included as a toxicity control. Individual scores were 
calculated on the basis of the relative percentage of deviation from the negative control quantified and assigned with 
a number from 0 to 5 (0 [0% to 20% deviation], 1 [20% to 40%], 2 [40% to 60%], 3 [60% to 100%], 4 [100% to 
1,000%], or 5 [1,000% deviation]). The data represent the mean sum of these values. (B) Neurotoxicity injury score. 
The score was calculated in a manner similar to that for the hepatotoxicity score, but instead of DNA damage by 
H2AX antibody, an assay to test neurite outgrowth as imaged with an anti-tubulin III antibody and HCA was 
performed. The data represent the mean sum of these values. Data are from 2 independent experiments 
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Figure 3. BNIPDabut in vivo efficacy against T. brucei brucei. (A) Schematic of the experimental design for 
evaluating the in vivo efficacy of BNIPDabut. (B) Mice were infected with 10
4 
luciferase-positive BSFs by 
intraperitoneal injection, and the different treatments were initiated 3 days after infection. Whole-mouse 
bioluminescence imaging was done on days 3, 4, 9, and 12 using an IVIS Lumina LT and after injection of 2.1 mg 
luciferin. The bioluminescence average radiance (photons per seconds per square centimeter per steradian 
[p/sec/cm
2
/sr]) of whole mice was quantified, and the meanstandard deviation (n=4) is shown by the bars. 
Parasitemia was determined with a hemocytometer, and the means + standard deviations are represented by red 
dots. Red X’s represent the parasite concentration of the only animal in which parasites could be detected and 
quantified. The parasitemia detection limit was 5 x 10
4
 parasites/ml. (C) Kaplan-Meyer survival curves of the infected 
mice treated with control and experimental doses of BNIPDabut. In panels B and C, the data are representative of 3 
independent experiments. 
